Simpson R J, Hammacher A, Smith D K, Matthews J M, Ward L D
Joint Protein Structure Laboratory, Ludwig Institute for Cancer Research, (Melbourne Tumour Biology Branch), Parkville, Victoria, Australia.
Protein Sci. 1997 May;6(5):929-55. doi: 10.1002/pro.5560060501.
Interleukin-6 (IL-6) is a multifunctional cytokine that plays a central role in host defense due to its wide range of immune and hematopoietic activities and its potent ability to induce the acute phase response. Overexpression of IL-6 has been implicated in the pathology of a number of diseases including multiple myeloma, rheumatoid arthritis, Castleman's disease, psoriasis, and post-menopausal osteoporosis. Hence, selective antagonists of IL-6 action may offer therapeutic benefits. IL-6 is a member of the family of cytokines that includes interleukin-11, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, and ciliary neurotrophic factor. Like the other members of this family, IL-6 induces growth or differentiation via a receptor-system that involves a specific receptor and the use of a shared signaling subunit, gp130. Identification of the regions of IL-6 that are involved in the interactions with the IL-6 receptor, and gp130 is an important first step in the rational manipulation of the effects of this cytokine for therapeutic benefit. In this review, we focus on the sites on IL-6 which interact with its low-affinity specific receptor, the IL-6 receptor, and the high-affinity converter gp130. A tentative model for the IL-6 hexameric receptor ligand complex is presented and discussed with respect to the mechanism of action of the other members of the IL-6 family of cytokines.
白细胞介素-6(IL-6)是一种多功能细胞因子,因其广泛的免疫和造血活性以及诱导急性期反应的强大能力,在宿主防御中发挥核心作用。IL-6的过表达与多种疾病的病理过程有关,包括多发性骨髓瘤、类风湿性关节炎、卡斯特曼病、银屑病和绝经后骨质疏松症。因此,IL-6作用的选择性拮抗剂可能具有治疗益处。IL-6是细胞因子家族的成员之一,该家族还包括白细胞介素-11、白血病抑制因子、制瘤素M、心肌营养素-1和睫状神经营养因子。与该家族的其他成员一样,IL-6通过一种受体系统诱导生长或分化,该受体系统涉及一种特异性受体并利用一个共享的信号亚基gp130。确定IL-6中与IL-6受体和gp130相互作用的区域是合理操控这种细胞因子的作用以获得治疗益处的重要第一步。在这篇综述中,我们聚焦于IL-6上与其低亲和力特异性受体IL-6受体以及高亲和力转换器gp130相互作用的位点。我们提出了一个关于IL-6六聚体受体配体复合物的初步模型,并就IL-6细胞因子家族其他成员的作用机制进行了讨论。